Surgical implications of platelet glycoprotein IIb-IIIa inhibition.
Duke
C
C
Grammie
J S
JS
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D007611:Aprotinin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001026:Coronary Artery Bypass; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019106:Postoperative Hemorrhage / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D006490:Hemostatics; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D007611:Aprotinin; D000077284:Abciximab